Company news

Candel Therapeutics, Inc. news in 2025

Candel Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

November 17, 2025

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 13, 2025

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

November 4, 2025

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

November 3, 2025

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

October 16, 2025

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

October 14, 2025

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

October 14, 2025

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

October 3, 2025

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 29, 2025

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

September 17, 2025

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

September 2, 2025

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

August 28, 2025

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 14, 2025

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

July 30, 2025

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

July 24, 2025

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

July 9, 2025

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

June 24, 2025

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

June 23, 2025

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 6, 2025

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 28, 2025

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 27, 2025

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 22, 2025

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025

Candel Therapeutics to Present at Upcoming Investor Conferences

May 6, 2025

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

April 23, 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

April 1, 2025

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

March 26, 2025

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

March 20, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board

March 18, 2025

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

March 13, 2025

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

February 25, 2025

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

January 12, 2025

Decks in 2025